Related Experiment Videos
Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk
Miki Ohira1, Shigeyuki Oba, Yohko Nakamura
1Division of Biochemistry, Chiba Cancer Center Research Institute, Chiba 260-8717, Japan.
Cancer Cell
|April 20, 2005
Summary
Researchers developed a gene microarray to predict neuroblastoma patient prognosis. This tool accurately identifies high-risk and low-risk patients, improving treatment strategies and survival predictions.
Area of Science:
- Oncology
- Genomics
- Biostatistics
Background:
- Neuroblastoma prognosis prediction is crucial for effective therapeutic strategies.
- Existing prognostic markers for neuroblastoma have limitations in accurately stratifying patients.
- A need exists for more precise tools to guide treatment decisions in neuroblastoma.
Purpose of the Study:
- To develop a gene expression-based prognostic tool for neuroblastoma.
- To improve the accuracy of predicting patient survival and outcomes.
- To identify distinct patient subgroups within intermediate-risk categories.
Main Methods:
- Utilized a cDNA microarray with 5340 genes from primary neuroblastoma samples.
- Examined 136 neuroblastoma tumor samples for gene expression profiling.
- Developed a probabilistic statistical classifier for prognosis prediction.
- Employed Kaplan-Meier analysis to validate prognostic groupings.
Main Results:
- The developed classifier achieved 89% accuracy in predicting 5-year survival.
- Microarray analysis refined existing intermediate-risk groups into two distinct prognostic categories (36% vs. 89% 5-year survival).
- A gene subset chip was created as a clinical tool, demonstrating 88% prediction accuracy.
Conclusions:
- Gene expression profiling via microarray offers a highly accurate method for neuroblastoma prognosis.
- This approach refines patient stratification, enabling more personalized therapeutic protocols.
- The developed gene subset chip serves as a reliable clinical tool for improved neuroblastoma management.